Thomas Gauler's research while affiliated with University of Duisburg-Essen and other places

Publications (65)

Article
Introduction: CeFCiD was a multicenter phase II study comparing the efficacy of cetuximab, 5-flourouracil, cisplatin with the same regimen adding docetaxel in recurrent/metastatic head and neck cancer. The primary analysis trial did not demonstrate survival benefit from therapy intensification in first-line recurrent and/or metastatic squamous cel...
Article
Full-text available
Purpose Accurate therapeutic management of the neck is a challenge in patients with supraglottic laryngeal cancer. Nodal metastasis is common at all disease stages, and treatment planning relies on clinical staging of the neck, for both surgical and non-surgical treatment. Here, we compared clinical and surgical staging results in supraglottic carc...
Article
Full-text available
Purpose: The aim of this study was to compare the pattern of intra-patient spread of lymph-node (LN)-metastases within the mediastinum as assessed by 18F-FDG PET/CT and systematic endobronchial ultrasound-guided transbronchial-needle aspiration (EBUS-TBNA) for precise target volume definition in stage III NSCLC. Methods: This is a single-center...
Article
Background In the Phase-III clinical trial, CheckMate 141, nivolumab significantly improved survival versus standard of care in patients with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Methods This pooled analysis investigated the real-world effectiveness of nivolumab, following prior platinu...
Article
Background Small cell lung cancer (SCLC), a highly aggressive solid tumor strongly associated to inhalative smoking of tobacco, shows a high response rate to chemotherapy but nevertheless has a very poor prognosis. Despite decades of intensive clinical research, it was just in the last two years that progress has been made in improving patient outc...
Article
Purpose/Objective(s): The aim of this follow-up analysis of the ESPATUE phase-3 trial was to explore the prognostic value of post-induction chemotherapy PET metrics in patients with stage III non-small cell lung cancer (NSCLC) who were assigned to receive definitive chemoradiotherapy. Materials/Methods: All eligible patients stage IIIA (cN2) and st...
Article
Full-text available
Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-based chemoimmunotherapy in r/m SCCHN. Against this...
Article
Full-text available
Identifying patients with locally advanced head and neck carcinoma on high risk of recurrence after definitive concurrent radiochemotherapy is of key importance for the selection for consolidation therapy and for individualized treatment intensification. In this multicenter study we analyzed recurrence-associated single-nucleotide polymorphisms (SN...
Article
Full-text available
Purpose: The aim of the present study based on the PriCoTTF-phase I/II trial is the quantification of skin-normal tissue complication probabilities of patients with newly diagnosed glioblastoma multiforme treated with Tumor Treating Field (TTField) electrodes, concurrent radiotherapy, and temozolomide. Furthermore, the skin-sparing effect by the c...
Article
Full-text available
This letter summarizes recommendations from the interdisciplinary working group of renal tumors (IAGN) of the German Cancer Society for the systemic treatment of advanced/metastatic renal cell carcinoma in the context of the current SARS-CoV-2 pandemic
Article
Background: CheckMate 025 has shown superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma (aRCC) along with improved safety and tolerability. This analysis assesses the long-term clinical benefits of nivolumab versus everolimus. Methods: The randomized, open-label, phase 3 CheckMate 025 trial (NCT01668784...
Article
Background: Non-clear cell renal cell cancers (nccRCC) are rare entities, and the optimal therapy in metastatic disease has still to be defined. Methods: In this small prospectively randomized phase IIa multicenter trial, we investigated temsirolimus (TEM) versus sunitinib (SUN) as first-line therapy in patients with metastatic nccRCC. The patie...
Article
6574 Background: DURTRERAD is a randomized phase II study evaluating feasibility and efficacy of durvalumab (anti-PD-L1) vs. durvalumab and tremelimumab (anti-CTLA-4) in combination with radiotherapy as primary treatment for locally advanced HPV negative HNSCC. (NCT03624231). Concurrent chemo-RT with a platinum-based regimen is considered the stand...
Article
6532 Background: Nivolumab has demonstrated efficacy in clinical trials of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). As only limited real-world data are available, we describe the use of nivolumab and its outcomes in routine clinical practice. Methods: HANNA is a prospective, observational study of patients w...
Article
Purpose To investigate whether potential differences in staging between a traditional staging imaging algorithm and ¹⁸F-FDG PET/MR lead to a change in patient management in breast carcinoma and to compare the diagnostic accuracy between the traditional staging algorithm and ¹⁸F-FDG PET/MR for the TNM classification. Method In this prospective coho...
Article
Background: The combination of cisplatin, 5-fluorouracil (5-FU) and cetuximab (PFC) is the reference first-line treatment for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). We analysed whether treatment intensification by the addition of docetaxel to PFC improved efficacy in R/M SCCHN. Methods: A total of 180 pa...
Article
Objectives: Patients with head and neck squamous cell carcinoma (HNSCC) can experience severe symptom burden and/or difficulty swallowing, leading to problems with treatment adherence/administration. In LUX-Head and Neck 1 (LH&N1; NCT01345682), second-line afatinib improved progression-free survival (PFS) versus methotrexate in patients with recur...
Article
Full-text available
Purpose According to the ACRIN 6668/RTOG 0235 trial, pretreatment metabolic tumour volume (MTV) as detected by ¹⁸F-fluorodeoxyglucose PET/CT is a prognostic factor in patients with stage III non-small-cell lung cancer (NSCLC) after definitive radiochemotherapy (RCT). To validate the prognostic value of MTV in patients with stage III NSCLC after RCT...
Article
8543 Background: A better understanding of molecular mechanisms governing clonal tumor evolution under RCHT is of utmost importance for development of novel biomarker and targeted therapies. We report here the first attempt to decipher RCHT induced cellular and molecular perturbation in NSCLC on an integrative multiscale level. Methods: Patients wi...
Article
Full-text available
Background Treatment options for patients (pts) with multiply relapsed or refractory metastatic germ cell cancer (GCC) are limited. The mTOR inhibitor everolimus has been approved for the treatment of different solid tumors and was assessed in refractory GCC within this phase II RADIT trial of the German Testicular Cancer Study Group. Methods GCC...
Article
Full-text available
Bone is a major site of haematogenous tumour cell spread in renal cell carcinoma (RCC), and most patients with RCC will develop painful and functionally disabling bone metastases at advanced disease stages. The prognosis of these patients is generally poor and the treatment is, therefore, aimed at palliation. However, RCC-associated bone metastases...
Article
Full-text available
Background: The randomized, phase 3 CheckMate 025 study of nivolumab (n=410) versus everolimus (n=411) in previously treated adults (75% male; 88% white) with advanced renal cell carcinoma (aRCC) demonstrated significantly improved overall survival (OS) and objective response rate (ORR). Objective: To investigate which baseline factors were asso...
Article
Background: Heart exposure to ionizing irradiation can cause ischemic heart disease. The partial heart volume receiving ≥5 Gy (heartV5) was supposed to be an independent prognostic factor for survival after radiochemotherapy for locally advanced non-small cell lung cancer (NSCLC). But validation of the latter hypothesis is needed under the concurr...
Article
Full-text available
Purpose: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carci...
Chapter
Ist die Indikation zur Strahlentherapie bei älteren Menschen gegeben, dann kann diese in vielen klinischen Situationen wie bei jüngeren Patienten durchgeführt werden. Hypofraktionierte Strahlentherapieschemata können insbesondere in der palliativen Situation die Gesamtbehandlungszeit verkürzen. Mit der bildgeführten hochkonformalen Strahlentherapie...
Article
Objective To investigate whether differences in thoracic tumour staging between 18F-FDG PET/CT and PET/MR imaging lead to different therapeutic decisions in Non-Small Cell Lung Cancer (NSCLC). Material and methodsSeventy-seven NSCLC patients that underwent whole-body 18F-FDG PET/CT from the base of skull to the upper thighs and thoracic PET/MR were...
Data
Flowcytometric immunophenotyping. Flowcytometric analysis and validation of the CD133 cell surface expression on K562 cells engineered to express the CD133 splice variant s1 encoded by an IRES-eGFP expression cassette (CD133:IEG). Cells were stained with PE-conjugated isotype control or anti-CD133 antibodies. (TIF)
Article
Full-text available
Purpose: Due to their minimal-invasive yet potentially current character circulating tumor cells (CTC) might be useful as a "liquid biopsy" in solid tumors. However, successful application in metastatic renal cell carcinoma (mRCC) has been very limited so far. High plasticity and heterogeneity of CTC morphology challenges currently available enric...
Article
Background: Large cell neuroendocrine carcinoma (LCNEC) is an uncommon tumor of the lung and represents approximately 3% of all lung cancers. LCNEC displays biological behaviors resembling those of small cell lung carcinomas and features of high-grade neuroendocrine tumors. LCNEC of the lung are considered aggressive. Reported prognoses are hetero...
Article
6065 Background: Treatment for patients with platinum-refractory metastatic squamous cell carcinoma of the head and neck (SCCHN) is limited. Cetuximab has been approved in the US in this patient population based on a phase II trial that demonstrated 13% response rate (RR) and 5.9 months median OS. A recently conducted phase III trial of zalutumumab...
Article
e19138 Background: D is an ATP competitive pan-aurora kinases inhibitor with activity also against FGFRs, VEGFR, Ret, TrkA, Scr, and Abl. Methods: Eligible pts had NSCLC progressing for advanced/metastatic disease after 1 prior chemotherapy line (CT). Primary endpoint was progression-free survival at 4 months (PFS-4) evaluated in a Simon two-stage...
Article
6002 Background: Sym004 is a first-in-class drug mixture of two mAbs targeting non-overlapping epitopes on the EGFR. In preclinical models, Sym004 exhibited more pronounced EGFR internalization, degradation and tumor growth inhibition than cetuximab. Sym004 was investigated as monotherapy in palliative squamous cell carcinoma of the head and neck (...
Article
e17021 Background: This study investigates efficacy and toxicity of docetaxel added to cetuximab, cisplatin and 5-FU for patients with R/M SCCHN. We here report a planned second interim analysis to compare response rates between arms in order to decide on continuing to full accrual. Methods: Inclusion criteria were: stage III/IV R/M SCCHN and ECOG...
Article
4559 Background: About 20-30% of patients (pts) with advanced germ-cell cancer (GCC) relapse after cisplatin-based chemotherapy. This database evaluates first salvage treatment and the prognostic categories at first relapse according to the International Prognostic Factors Study Group (= IPFSG; JCO 2010). Methods: A total of 144 pts (78% nonseminom...
Article
e17015 Background: Cetuximab has established activity in rmSCCHN as a single agent as well as in conjunction with chemotherapy. Combination treatment protocols lead to significant toxicity. It would be of interest to identify pretreatment characteristics and early indicators of long-term cetuximab efficac. Methods: rmSCCHN patients were analysed, w...
Article
189 Background: Validated biomarkers for patients (pts) with advanced pancreatic cancer (APC) treated with anti-EGFR drugs have not yet been defined. pERK represents the downstream target of the RAS-RAF-MEK cascade. Methods: Within AIO-PK0104 281 pts with APC were randomized between gemcitabine/erlotinib followed by capecitabine and capecitabine/er...
Article
5516^ Background: Prognosis for patients with recurrent and/or metastatic squamous cell cancer of the head and neck (R/M-SCCHN) is very poor. αvβ5 integrin is overexpressed in SCCHN and selective integrin blockade is being investigated as a treatment strategy. Methods: ADVANTAGE was a phase I/II study evaluating cilengitide with cetuximab and plati...
Article
e15026 Background: High-dose VIP chemotherapy plus ABSCT given as first line treatment might be a strategy in patient with advanced germ cell tumors (GCT) with poor prognosis. The objective of the trial was to investigate the addition of darbepoetin alfa to HD-VIP in order to reduce anemia/red blood cell (RBC) transfusions. Methods: This was a rand...
Article
4023 Background: AIO-PK 0104 investigated the efficacy and safety of gemcitabine/erlotinib (G/E) followed by capecitabine (C) vs. C/E followed by G. The present subgroup analysis evaluated the correlation between C-associated skin toxicity and outcome parameters in PC. Methods: Within this multicenter phase III trial, pts with confirmed advanced PC...

Citations

... 243,244 For patients receiving chemoradiation, several factors are of prognostic significance. [244][245][246] Yet, current clinical and imaging parameters are still imperfect in terms of prognostic power. [244][245][246] The added value of radiomics signature to SUVs or clinical factors in NSCLC patients undergoing chemoradiation has been described (AUCs: 0.72-0.79) ...
... Therefore, in most centers, routine elective neck dissection of both sides of the neck is performed in clinically and radiologically N0 patients with supraglottic carcinoma. [11] Simultaneous neck dissection of the opposite side may have some side effects, such as prolonged operation time, risk of ansa cervicalis injury in both sides, and increased laryngeal edema, which delays decannulation and swallowing rehabilitation. Thus, a contralateral neck dissection without oncological benefits will cause a delay in the patient's postoperative rehabilitation process. ...
... Recently, the prediction algorithm for skin irritation probability was presented. According to it, the variation of array positioning reduced the risk of skin irritation by about one-third (33). Moreover, practical suggestions for dermatological symptomatic treatment have been distributed (34). ...
... Nivolumab is an ICI that blocks the interaction between programmed cell death protein-1 (PD-1) expressed on T cells and its ligands programmed cell death protein ligand-1 (PD-L1) and PD-L2, expressed on antigen-presenting cells and cancer cells [12,13]. The efficacy and safety of nivolumab has been demonstrated in Check-Mate 025 (NCT0166874), a phase III randomised controlled trial (RCT) of nivolumab monotherapy in patients with refractory aRCC [14]. Patients in the nivolumab monotherapy arm had significantly longer median overall survival (OS) and more favourable safety outcomes compared with patients who received the comparator, everolimus [15,16]. ...
... Currently, there are few studies on immunotherapy towards HPV-negative OPSCC. DURTRERAD is a randomized phase II trial evaluating feasibility and efficacy of durvalumab (D arm) versus durvalumab and tremelimumab (DT arm) in combination with radiotherapy as primary treatment for locally advanced HPV-negative HNSCC, more than a half being OPSCC (97). In this trial, the DT arm was halted due to increased toxicity. ...
... In addition to imaging, serum tumor markers are the most common diagnostic means of cancer. Alpha-fetoprotein (AFP) is currently the most common tumor marker in the diagnosis of liver cancer, but clinical experience has revealed its mediocre sensitivity and specificity [10]. A previous study showed that the sensitivity and specificity of AFP for detecting hepatocellular carcinoma was 67.62% and 96.06% [11]. ...
... The AIO-PK0104 phase III randomized controlled study tested the safety and efficacy of the combination of capecitabine and erlotinib, followed by gemcitabine on progression (Group 1) versus gemcitabine plus erlotinib, followed by capecitabine on progression (Group 2) in advanced pancreatic cancer patients [4]. The authors of this study underwent a subgroup analysis evaluating the association of hand and foot skin toxicity with clinical outcome (Abstract #4023) [5]. In this study, 279 patients were treated with the above combinations, of whom 141 received subsequently the 2 nd line single agent (gemcitabine or capecitabine) on progression. ...
... Preclinical pharmacokinetic studies in primates and early clinical trial safety and feasibility studies in humans indicate that Sym004 is well-tolerated and does not induce unexpected toxicities (30). Several clinical trials are in progress to evaluate the clinical potential of Sym004 for patients with HNSCCs and metastatic colorectal cancer (31,32). With mature clinical trial data showing a modest survival advantage ($10%) for patients with HNSCCs treated with cetuximab with radiation (7), the more powerful impact of Sym004 compared with cetuximab in the current report provides a rationale to design clinical studies to test the impact of Sym004 with radiation for patients with HNSCCs in an effort to further improve overall outcome. ...